The UK government reported that GSK’s Belimumab (Benlysta) have revealed in clinical trials to show an increased risk of depression, suicidal ideation or behavior, or self-injury in patients with systemic lupus erythematosus. The UK government is warning physicians and investigators to assess patients for these risks before the start of treatment with belimumab.
Adverse Event: GSK’s Belimumab Increased Risk of Serious Psychiatric Events Seen in Clinical Trials
